RxDoctor Payments Data

Ravi Prasad Avati Nanjundappa, MD

Cardiovascular Disease · Middleburg, FLNPI 1679780373

Payments from drug & device makers

$3,206in general payments, 2019–2025

Across 37 payments — averaging $86.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Abbott$699
  • Abiomed$242
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$169
  • Novartis$147
  • Johnson & Johnson$134
  • plus $191 from 5 others

What the payments were for

  • Travel & lodging$1,25939%
  • Food & beverage$1,94661%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,206 in reported general payments places this provider in the 45th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$249,360
Medicare patients
1,482
Services billed
4,045

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban360$414,341
EntrestoSacubitril/Valsartan153$193,856
JardianceEmpagliflozin36$48,857
XareltoRivaroxaban43$48,812
BrilintaTicagrelor16$11,334
Metoprolol Succinate414$4,944
Atorvastatin Calcium361$3,603
Carvedilol355$2,549
Diltiazem 24hr Er (Cd)Diltiazem Hcl108$2,446
Bumetanide59$2,394
Losartan Potassium271$2,193
Chlorthalidone112$1,944
ClopidogrelClopidogrel Bisulfate120$1,442
Valsartan65$1,302
Lisinopril202$1,195

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$147$193,856153 claims
Boehringer IngelheimJardiance$18$48,85736 claims
Johnson & JohnsonXarelto$134$48,81243 claims
AstraZenecaBrilinta$28$11,33416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Middleburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →